https://www.selleckchem.com/pr....oducts/way-309236-a.
Liquid biopsy tests used to determine eligibility for PARP inhibition among men with advanced prostate cancer are prone to false positives because of interference from clonal hematopoiesis-but analyzing plasma cell-free DNA alongside paired whole-blood control samples can correct this problem.The NCI and Cancer Research UK have launched Cancer Grand Challenges, a $380 million initiative to fund global research on some of the most pressing issues in cancer research. For the first round of funding, the program plans to select up to f
Like
Comment
Share
